Il-2 dependent nk-92 cells with stable fc receptor expression
Patent Information
- Application Number
- HK42026126127
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-11-26
- Filing Date
- 2026-07-14
- Publication Date
- 2026-09-11
Smart Images

Figure 00000037_0000 
Figure 00000037_0001 
Figure 00000038_0000
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202511512037.7 (22) Application Date 2019.11.25 (30) Priority Data 62 / 771479 2018.11.26 US (62) Divisional Application Data 201980077301.5 2019.11.25 (71) Applicant: Immunobio Corporation Address: California, USA (72) Inventors: F. Navarro, H.G. Klingerman, L.H. Boisel, A. Dandapatty (74) Patent Agency: China Patent Agency (Hong Kong) Limited 72001 Patent Attorney: Peng Chang (51) Int.Cl. C12N 5 / 10 (2006.01) C12N 15 / 867 (2006.01) C12N 15 / 12 (2006.01) C07K 14 / 735 (2006.01) A61K 35 / 17 (2025.01) A61P 35 / 00 (2006.01) (54) Invention Title: IL-2-dependent NK-92 cells with stable Fc receptor expression (57) Abstract: This document provides an IL2-dependent cell population expressing high-affinity CD16 but not IL-2. These cells maintain stable expression of the Fc receptor CD16 while retaining cytotoxicity. In some embodiments, the expression level of CD16 is reduced by no more than 20% when the cells are activated compared to the CD16 expression level on the cells before activation. Compositions and kits comprising said cells are also provided, as well as methods for manufacturing and using IL2-dependent cells. Claims (2 pages), Description (34 pages), Sequence Listing (electronic publication), Drawings (8 pages), CN 121518401 A 2026.02.13 CN 1 21 51 84 01 A 1. The modified cell population according to claim 32, wherein the Fc receptor is CD16 (SEQ ID NO: 1), wherein the modified cells do not express IL-2, and wherein the population comprises one or more of the modified cells. 2. The modified cell population according to claim 1, wherein the modified cells contain the nucleic acid of CD16 (SEQ ID NO: 2). 3. The modified cell population according to claim 1, wherein the modified cells have antibody-dependent cell-mediated cytotoxicity (ADCC). 4. The modified cell population according to claim 1, wherein the CD16 expression level is reduced by no more than 20% when the cells are activated compared to the CD16 expression level on the cells before activation. 5. The modified cell population according to claim 4, wherein the cell population in6. The modified cell population according to any one of claims 1-4, wherein the cells express a higher level of CD16 than NK cells from the donor. 7. The modified cell population wherein, compared to the cells before activation, the percentage of CD16-positive cells decreases by no more than 20% after activation. 8. The modified cell population according to claim 4, wherein CD16 expression is measured by flow cytometry. 9. The population according to claim 4, wherein the activation is PHA stimulation, activation via an innate pathway through co-incubation with K562 cells, or ADCC activation through co-incubation with rituximab and DOHH. 10. The population according to claim 4, wherein the cells are activated by one or more compounds selected from PMA, ionomycin, and LPS. 11. The modified cell population according to claim 4, wherein the cells are activated by contact with target tumor cells. 12. The modified cell population of claim 11, wherein the target tumor cells are selected from K562 cells and SKBR-3 cells. 13. The modified cell population of claim 11, wherein CD16 expression is reduced by no more than 10% compared to the modified cells before activation, or wherein... 14. The modified cell population of claim 11, wherein CD16 expression is reduced by no more than 5% compared to the modified cells before activation. 15. The modified cell population of claim 11, wherein the percentage of CD16-positive cells is reduced by no more than 10% after contact with the target cells compared to the cells before contact with the target cells. 16. The modified cell population of claim 4, wherein the cells are activated by contact with an antibody and a target cell, wherein the incubation results in ADCC. 17. The modified cell population of claim 16, wherein the antibody is an anti-CD20 antibody, and the target cells are DOHH-2 cells. 18. The modified cell population of claim 16, wherein the antibody is an anti-HER2 antibody, and the target cells are SKBR3 cells. 19. The modified cell population of claim 16, wherein the effector-target ratio is 1:1 to 1:10. 20. The modified cell population of claim 1, wherein the modified cells further express a chimeric antigen receptor. 21. The modified cell population of any one of claims 1-20, wherein when the effector-target ratio is...At a target ratio of 5:1, the modified cells exhibit at least 60% direct cytotoxicity. 22. The modified cell population according to any one of claims 1-20, wherein the modified cells exhibit at least 40% ADCC activity. 23. A method for generating a modified cell population capable of maintaining CD16 expression during activation, wherein the method comprises introducing CD16 (SEQ ID NO: 2) instead of IL-2 into cells, wherein CD16 expression on the activated modified cells is not less than 50% of CD16 expression on the modified cells before activation. 24. The method according to claim 23, wherein the introduction of CD16 is via lentiviral infection. 25. A kit comprising a cell population according to any one of claims 1-22. 26. The kit according to claim 25, wherein the kit further comprises an antibody. 27. A pharmaceutical composition comprising a cell population according to any one of claims 1-22 and a pharmaceutically acceptable excipient. 28. A method of treating a subject, comprising administering the pharmaceutical composition of claim 27 to the subject. 29. The modified cell population of claim 1, wherein the modified cells further express a suicide gene. 30. The modified cell population of claim 29, wherein the suicide gene is selected from thymidine kinase (TK) gene, cytosine deaminase, cytochrome P450, and iCas9. 31. A modified cell population expressing an Fc receptor, wherein the Fc receptor comprises at least 80% of the same amino acid sequence as SEQ ID NO: 1, wherein the modified cells do not express IL-2, and wherein the population comprises one or more of the modified cells. 32. The modified cell population wherein the Fc receptor comprises at least 90% of the same amino acid sequence as SEQ ID NO: 1. Claims 2 / 2 Page 3 CN 121518401 A IL-2-dependent NK-92 cells with stable Fc receptor expression
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 771,479, filed November 26, 2018. For all purposes, the contents of the provisional application are incorporated herein by reference in their entirety. Background Art
[0003] Anticancer treatment with monoclonal antibodies has significantly improved clinical outcomes for cancer patients. One of the main mechanisms of action of therapeutic antibodies is through antibody-dependent cell-mediated cytotoxicity (ADCC). Natural killer cells can be used as cytotoxic effector cells for cell-based immunotherapies because they are the primary effector cells for ADCC.
[0004] The antibody referred to herein is found in the blood of subjects with non-Hodgkin lymphoma.Furthermore, an in vitro immortalized cell-lysing cancer cell line was developed. The cells were derived from NK cells but lacked the major inhibitory receptors present on normal NK cells, while retaining most of the activating receptors. However, the cells did not attack normal cells or elicit an unacceptable immune rejection response in the human body. Characterization of the cell line is disclosed in WO 1998 / 49268 and U.S. Patent Application Publication No. 2002-0068044. The cells have also been evaluated as potential therapeutic agents for certain cancers.
[0005] Although the cells retain almost all the activating receptors and cell-lysing pathways associated with NK cells, they do not express CD16 on their cell surface. CD16 is an Fc receptor that recognizes and binds to the Fc portion of antibodies to activate NK cells for ADCC effector mechanisms. Due to the lack of CD16 receptors, the unmodified cells cannot lyse target cells via ADCC mechanisms.
[0006] Naturally occurring NK cells express CD16, but when NK cells are activated by various stimuli, CD16 is susceptible to ADAM17-mediated proteolytic cleavage. For example, it is known that co-culturing NK cells with K562 tumor cells stimulates CD16-cleaving proteases, which leads to the shedding of CD16 expression on the surface of NK cells. This rapid downregulation of CD16 in NK cells after activation severely impairs ADCC activity.
[0007] This invention provides modified cell populations, compositions and kits comprising these cells, and methods for preparing and using these cell populations. The modified cells express CD16 (e.g., a high-affinity variant of the Fc receptor CD16) but not IL-2. These modified cells exhibit high levels of CD16 expression and maintain this expression level during and / or after activation by stimulants, target cell binding, or ADCC. This stable expression of CD16 enables the modified cells to achieve continuous killing of target cells during and / or ADCC. Excluding IL-2 transgenes from the modified cells minimizes the negative effects of IL-2 transgenes and allows for the flexible introduction of additional transgenes that can confer the desired properties of the modification. For example, IL-2 may be released in vivo due to cell leakage or cell death. IL-2 can promote the recruitment and expansion of Tregs, leading to immunosuppression. High doses of IL-2 have been shown to induce strong side effects in patients, such as an increased risk of infection, bruising and bleeding, and fatigue. See https: / / www.cancerresearchuk.org / about-cancer / cancer-in-general / treatment ...
[0008] The modified cells described above are referred to herein as “IL2-dependent CD16-positive cells” or “IL2-dependent cells”.
[0009] In some embodiments, this disclosure provides a modified cell population expressing CD16 (SEQ ID NO: 1), wherein the modified cells do not express IL-2, and wherein the population comprises one or more modified cells. The modified cells may contain the nucleic acid of CD16 (SEQ ID NO: 2). In some embodiments, the modified cells have ADCC.
[0010] In some embodiments, the CD16 expression level of the modified cells is reduced by no more than 20% when the cells are activated compared to the CD16 expression level on the cells before activation. In some embodiments, the percentage of CD16-positive cells is reduced by no more than 10% after the cells are contacted with the target cells compared to the cells before contact.
[0011] In some embodiments, the modified cells do not show a reduction in CD16 expression or a reduction in CD16 expression of no more than 20% after activation, and wherein the modified cells maintain cytotoxic homeostasis for at least 5 hours after activation begins.
[0012] In some embodiments, the cells express a higher level of CD16 than NK cells from a donor. In some embodiments, CD16 expression is measured by flow cytometry. In some embodiments, the percentage of CD16-positive cells is reduced by no more than 20% after activation compared to pre-activation cells. In some embodiments, the cells are activated by one or more compounds selected from PMA, iomycin, and LPS. In some embodiments, the modified cells are activated via phytohemagglutinin (PHA), via an innate pathway through co-incubation with K562 cells, or via ADCC co-incubation with rituximab and DOHH.
[0013] In some embodiments, the modified cell population is activated by contact with target tumor cells. The target tumor cells may be cells selected from K562 cells and SKBR-3 cells. In some embodiments, the CD16 expression of the activated modified cell population is reduced by no more than 10% compared to pre-activation modified cells. In some embodiments, the CD16 expression level on the activated cells is reduced by no more than 5% compared to the CD16 expression level on the pre-activation modified cells.
[0014] In some embodiments, the modified cell population is activated by contact with the antibody and target cells, wherein incubation leads to ADCC. In some embodiments, the antibody is an anti-CD20 antibody, and the target cells are DOHH-2 cells. In some embodiments, the antibody is an anti-HER2 antibody, and the target cells are SKBR3 cells. In some embodiments, the ratio of modified cells to target cells is in the range of 1:1 to 1:10, including the endpoints. In some embodiments...The modified cell population according to any one of claims 1-18, wherein the modified cells have at least 60% direct cytotoxicity when the effect-target ratio of a cytotoxicity assay is 5:1. In some embodiments, the modified cells have at least 40% ADCC activity.
[0015] In some embodiments, the modified cells additionally express a chimeric antigen receptor.
[0016] In some embodiments, the modified cells additionally express a suicide gene. In some embodiments, the suicide gene is selected from thymidine kinase (TK) gene, cytosine deaminase, cytochrome P450, and iCas9. Specification 2 / 34 pages 5 CN 121518401 A
[0017] In some embodiments, this disclosure provides a method for generating a modified cell population capable of maintaining CD16 expression during activation, wherein the method includes introducing CD16 (SEQ ID NO: 2) instead of IL-2 into cells, wherein CD16 expression on activated modified cells is not less than 80% of CD16 expression on pre-activated modified cells. In some embodiments, CD16 introduction is achieved through lentiviral infection.
[0018] In some embodiments, this disclosure also provides a kit comprising a cell population of any of the embodiments described above. In some embodiments, the kit further comprises an antibody.
[0019] In some embodiments, this disclosure also provides a pharmaceutical composition comprising a cell population of any of the embodiments described above and a pharmaceutically acceptable excipient. In some embodiments, this disclosure provides a method of treating a subject, comprising administering the pharmaceutical composition described herein to the subject. Brief Description of the Drawings
[0020] Figures 1A and 1B show the results of flow cytometry analysis of CD16 expression on “haNK003 cells” (non-IL-2 dependent cells expressing CD16), IL2 dependent cells, and donor NK cells before (Figure 1A) and after (Figure 1B) PMA / ionomycin treatment.
[0021] Figures 2A-2C show the results of flow cytometry analysis of CD16 expression on haNK003 cells, IL2 dependent cells, and donor NK cells. Figure 2A shows CD16 expression on cells before co-culturing with K562 cells, Figure 2B shows CD16 expression after co-culturing with K562 cells for 4 hours, and Figure 2C shows CD16 expression after co-culturing for 24 hours.
[0022] Figures 3A and 3B show the CD16 expression levels in haNK003 cells and IL2-dependent cells after ADCC. ADCC was performed by co-culturing DoHH cells with 1 μg / ml rituximab at an E:T ratio of 1:0 (effect only) to 1:4 for 4 hours, followed by measuring CD16 expression levels at 4 hours and 24 hours by flow cytometry.Figure 3A shows flow cytometry analysis of CD16 expression levels in haNK-003 and IL2-dependent cells after ADCC and control (E:T=1:0). Figure 3B shows the median fluorescence intensity (MFI) of CD16 expression at 4 hours and 24 hours.
[0023] Figure 4 shows the median fluorescence intensity (MFI) of CD16 surface staining in haNK003 cells and IL2-dependent clones (H2, H7, H20, P74, P82, and P110) at various time points within 24 weeks after aNKTM cells were infected with lentiviruses carrying CD16 transgenes.
[0024] Figures 5A and 5B show the K562 cell lysis by mixing aNKTM cells, haNK003 cells, and IL2-dependent cells with K562 cells at different effector-target ratios.
[0025] Figures 6A and 6B show antibody-dependent cell-mediated cytotoxicity (ADCC) of IL2-dependent cells (Figure 6A: H clone and Figure 6B: P clone) against SKBR-3 cells at an effector-target ratio of 10:1 in the presence of Herceptin. The Y-axis value was determined by subtracting the percentage of SKBR-3 cells lysed by IL2-dependent cells in the presence of the isotype control antibody from the percentage of IL2-dependent cell lysis in the presence of Herceptin under the same conditions. Detailed Description
[0026] This document provides modified cells, namely IL2-dependent cells, that express a high-affinity variant of the Fc receptor CD16, and thus enable CD16-targeted antibody-dependent cell-mediated cytotoxicity (ADCC). (Specification 3 / 34 pages 6 CN 121518401 A) The IL2-dependent cells disclosed in this application do not express interleukin 2 (IL-2), such as human IL-2 (GenBaNK™ accession number: AAH70338.1) or any polypeptide containing the amino acid sequence of IL-2.
[0027] ADCC is mediated by recognizing the Fc fragment of a target-bound antibody (IgG) via the CD16 Fc receptor, which activates modified cells for targeted killing. ADCC is important for many therapeutic applications. For example, ADCC of IL2-dependent cells can be triggered by the binding of the CD16 receptor to the Fc fragment of a target-bound IgG to activate IL2-dependent cells for targeted killing.
[0028] In response to certain stimuli, CD16 is cleaved near the cell membrane, resulting in the release of the extracellular portion of the receptor and downregulation of its expression after activation (see Jing et al., PLOS one, 10(3): e0121788 DOI: 10.1371 / journal.pone.0121788(2015)). Under normal circumstances, this mechanism helps control the cytotoxicity of NK cells.However, in a tumor environment, this may reduce ADCC efficacy and cancer cell killing. Advantageously, the IL2-dependent cells provided in this disclosure exhibit superior ADCC activity against cancer cells, which is theoretically possible, but not limited to, the fact that CD16 expression levels are maintained during and / or after ADCC. With respect to the modified cells disclosed herein, ADCC activity refers to the ability to kill target cells by ADCC. In an exemplary embodiment, ADCC activity can be determined by the following formula: [% killing in the E+T reaction in the presence of mAb - % killing in the E+T reaction in the absence of mAb] / [100 - % killing in the E+T reaction in the absence of mAb], where E refers to the modified cells, T refers to the target cells, mAb refers to the target antibody, and % killing refers to the percentage of cells lysed in the reaction.
[0029] The IL2-dependent cells provided in this disclosure are generated by stable transfection of cells with a plasmid containing the sequence of CD16, high-affinity Fc-γ receptor (FcγRIIIa / CD16a), SEQ ID NO: 1. IL2-dependent cells do not express IL-2. Therefore, this disclosure provides a modified cell population with antibody-dependent cell-mediated cytotoxicity (ADCC), i.e., IL2-dependent cells, comprising a nucleic acid molecule containing CD16 (SEQ ID NO: 2).
[0030] Optionally, the modified cells comprise a nucleic acid sequence having 70%, 80%, 90%, or 95% identity with SEQ ID NO: 2. Optionally, the modified cells comprise a nucleic acid sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 2. Optionally, the modified cells comprise a polypeptide having 70%, 80%, 90%, or 95% identity with SEQ ID NO: 1. Optionally, the modified cells comprise a polypeptide having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO: 1.
[0031] Terminology
[0032] As used herein, nucleic acid refers to deoxyribonucleotides or ribonucleotides and their polymers and complements. The term includes deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form. The term includes nucleic acids containing known nucleotide analogs or modified backbone residues or linkages (which are synthetic, naturally occurring, and non-naturally occurring), having binding properties similar to a reference nucleic acid, and being metabolized in a manner similar to a reference nucleotide. Examples of such analogs include, but are not limited to, thiophosphates, aminophosphates, methylphosphonates, chiral methylphosphonates, 2-O-methylribonucleotides, and peptide nucleic acids (PNAs). Unless otherwise stated, conserved modified variants of nucleic acid sequences (e.g., degenerate codon substitutions) and complementary sequencesIt can be used to replace the specific nucleic acid sequences described herein. Specifically, degenerate codon substitution can be achieved by generating a sequence in which the third position of one or more selected (or all) codons is replaced by a mixture of bases and / or deoxyinosine residues. (See specification 4 / 34, page 7, CN 121518401 A (Batzer et al., Nucleic Acid Res. 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8: 91-98 (1994)). The term "nucleic acid" is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
[0033] When a nucleic acid forms a functional relationship with another nucleic acid sequence, the nucleic acid is operatively linked. For example, if the DNA encoding a pre-sequence or secretory leader sequence is expressed as a pre-protein involved in polypeptide secretion, it is operatively linked to the DNA encoding the polypeptide; if a promoter or enhancer affects the transcription of a coding sequence, it is operatively linked to that coding sequence; or if the ribosome binding site is localized to facilitate translation, it is operatively linked to the coding sequence (if it is localized to facilitate translation). Generally, operative linking means that the linked DNA sequences are close to each other and, in the case of a secretory leader sequence, are contiguous and in the reading phase. However, enhancers do not have to be contiguous. For example, a nucleic acid sequence operatively linked to a second nucleic acid sequence is covalently linked directly or indirectly to such a second sequence, although any effective three-dimensional association is acceptable. A single nucleic acid sequence can be operatively linked to multiple other sequences. For example, a single promoter can direct the transcription of multiple RNA species. Linking can be accomplished by joining at a convenient restriction site. If such a site is not available, synthetic oligonucleotide adaptors or linkers are used as is standard practice.
[0034] The term “polypeptide” as used herein generally has the meaning of a polymer of at least three amino acids as understood in the art, and is intended to include both peptides and proteins. However, the term is also used to refer to specific functional classes of polypeptides, such as desaturases, elongases, etc. For each of these classes, this disclosure provides several examples of known sequences of such polypeptides. However, those skilled in the art will understand that the term “polypeptide” is intended to be broad enough to include not only polypeptides having the complete sequence described herein (or in references or databases specifically mentioned herein), but also polypeptides representing functional fragments of such complete polypeptides (i.e., fragments that retain at least one active component). Furthermore, those skilled in the art will understand that protein sequences generally tolerate certain substitutions without destroying activity. Thus, any polypeptide that retains activity and shares at least one amino acid with another polypeptide of the same class is considered a valid polypeptide.A polypeptide with approximately 30-40% overall sequence identity (typically greater than approximately 50%, 60%, 70%, or 80%, and typically further including at least one region with much higher identity, typically greater than 90% or even 95%, 96%, 97%, 98%, or 99% in one or more highly conserved regions (typically containing at least 3-4 and typically up to 20 or more amino acids) is included within the relevant term "polypeptide" as used herein. Those skilled in the art can determine other regions of similarity and / or identity by analyzing the sequences of the various polypeptides described herein. As is known to those skilled in the art, various strategies are known, and tools can be used to compare amino acid or nucleotide sequences to assess the degree of identity and / or similarity. These strategies include, for example, manual alignment, computer-aided sequence alignment, and combinations thereof. Various algorithms for performing sequence alignment (which are typically computer-executed) are widely available or can be generated by those skilled in the art. Representative algorithms include, for example, the local homology algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2: 482); the homology comparison algorithm of Needleman and Wunsch (J. Mol. Biol., 1970, 48: 443); the similarity retrieval method of Pearson and Lipman (Proc. Natl. Acad. Sci. (USA), 1988, 85: 2444); and / or computerized implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wisconsin). Easily available computer programs integrating these algorithms include, for example, BLASTN, BLASTP, Gapped BLAST, PILEUP, CLUSTALW, etc. When using BLAST and Gapped BLAST programs, the default parameters of the respective programs can be used. Alternatively, practitioners may use non-default parameters according to their experiments and / or other requirements (e.g., see the website www.ncbi.nlm.nih.gov).
[0035] The term “transformation” as used herein refers to the process by which a foreign or heterologous nucleic acid molecule (e.g., a vector or recombinant nucleic acid molecule) is introduced into a recipient cell or microorganism. The foreign or heterologous nucleic acid molecule may be integrated or not integrated into (i.e., covalently linked to, on page 5 / 34 of the specification, CN 121518401 A) the chromosomal DNA constituting the genome of the host cell or microorganism. For example, foreign or heterologous polynucleotidesIt can be retained on free-body elements such as plasmids. Optionally or additionally, exogenous or heterologous polynucleotides can be integrated into chromosomes, thereby enabling cellular heredity through chromosome replication. Methods for transformation include, but are not limited to, calcium phosphate precipitation; fusion of recipient cells with bacterial protoplasts containing recombinant nucleic acids; treatment of recipient cells with liposomes containing recombinant nucleic acids; DEAE dextran; fusion using polyethylene glycol (PEG); electroporation; magnetic perforation; gene gun delivery; retroviral infection; lipid transfection; and direct microinjection of DNA into cells.
[0036] The term “transformed,” as used when referring to cells, means a cell that has undergone transformation as described herein, such that the cell carries exogenous or heterologous genetic material (e.g., recombinant nucleic acids). The term “transformed” may also or alternatively be used to refer to microorganisms, microbial strains, tissues, organisms, etc., containing exogenous or heterologous genetic material.
[0037] When referring to cells, nucleic acids, peptides, vectors, etc., the terms “modified” and “recombinant” indicate that the cell, nucleic acid, peptide, vector, etc., has been modified by laboratory methods or is the result of laboratory methods and is not naturally occurring. Thus, for example, modified cells include cells produced or modified by laboratory methods (e.g., transformation methods for introducing nucleic acids into cells). Modified cells may include nucleic acid sequences not found in the natural (non-recombinant) form of the cell, or may include altered nucleic acid sequences, such as nucleic acid sequences linked to non-natural promoters.
[0038] As used herein, the term “effect-target ratio” refers to the ratio of the number of effector cells (e.g., cells such as IL2-dependent cells) to the number of target cells (e.g., tumor cells) used in an analysis to assess the cytotoxicity of effector cells to target cells.
[0039] As used herein, “natural killer (NK) cells” refers to immune system cells that kill target cells without specific antigenic stimulation and is not limited according to major histocompatibility complex (MHC) categories. Target cells may be cancer cells or tumor cells. NK cells are characterized by the presence of the CD56 surface marker and the absence of the CD3 surface marker.
[0040] As used herein, “cell” refers to a natural killer cell derived from a highly potent and unique cell line as described by Gong et al. (1994), the rights of which are owned by NantKwest.
[0041] For the purposes of this invention and unless otherwise stated, the term or “NK 9 2” means the original cell line as well as a modified cell line (e.g., by introducing a foreign gene), a clone of a cell, and a cell. Cells and their exemplary and non-limiting modifications are described in U.S. Patent Nos. 7,618,817; 8,034,332; 8,313,943; 9,181,322; 9,150,636; and U.S. Application 10 / 008.In accordance with reference to 955, the entire contents of which are incorporated herein by reference, including wild-type -CD16, -CD16-γ, -CD16-ζ, -CD16(F176V), MI, and CI. Cells are known to those skilled in the art and readily available to them from NantKwest, Inc. As used herein, the term "aNK™ cell" refers to an unmodified natural killer cell derived from the highly potent, unique cell line described in Gong et al. (1994), the rights of which are owned by NantKwest. As used herein, the term "cell" refers to a natural killer cell derived from the highly potent, unique cell line described in Gong et al. (1994), the rights of which are owned by NantKwest, modified to express CD16 on its cell surface (hereinafter, "CD16-positive cell" or "cell"). Therefore, examples of cells include IL2-dependent cells (“haNK003 cells”) and IL2-dependent cells – the former additionally expressing recombinant IL-2, while the latter does not.
[0042] As used herein, the term “NK cell” refers to a) donor-derived NK cells, b) NK-92.176V-CD16.ERIL2 cells (i.e., non-IL2-dependent cells) and c) NK-92.176V-CD16 cells (i.e., IL2-dependent cells). As disclosed herein, donor-derived NK cells exhibit rapid and deep reductions in CD16 expression upon activation, with only marginal recovery of expression after overnight recovery, while cells (IL2-dependent and non-dependent similar) exhibit little or no reduction in CD16 expression while maintaining peak cytotoxic potency.
[0043] The term “Fc receptor” refers to a protein found on the surface of certain cells (e.g., natural killer cells) that causes the protective function of immune cells by binding to antibody regions called Fc regions. The binding of an antibody’s Fc region to a cell’s Fc receptor (FcR) stimulates phagocytic or cytotoxic activity of the cell through antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity (ADCC). FcRs are classified according to the type of antibody they recognize. For example, the Fc-γ receptor (FcγR) binds to IgG antibodies. FcγRIII-A (also known as CD16) is a low-affinity Fc receptor that binds to IgG antibodies and activates ADCC. FcγRIII-A is commonly found on NK cells. Cells do not express FcγRIII-A. A representative amino acid sequence encoding CD16 is shown in SEQ ID NO: 1. A representative polynucleotide sequence encoding CD16 is shown in SEQ ID NO: 1.NO: 2. The complete sequence of CD16 can be found in the SwissProt database as entry P08637.
[0044] As used herein, the term “activation” refers to the phenomenon of NK cells being stimulated to perform cytotoxic functions by contact with one or more activators (stimulants). These cytotoxic functions may include the release of cytoplasmic proteins, such as perforin and proteases called granzymes, to induce apoptosis or lysis of closely adjacent cells. These activators include, but are not limited to, various cytokines (e.g., interferons or macrophage-derived cytokines), phytohemagglutinins (e.g., phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM)), lipopolysaccharide (LPS), PMA (phorbol 12-myristate 13-acetate) / ionomycin, and purified protein derivatives of tuberculin (PPD). Activation can refer to a) PHA stimulation, b) activation via the innate pathway through co-incubation with K562, or c) ADCC activation through co-incubation with rituximab and DOHH.
[0045] In some embodiments, the activator can be tumor cells. In some embodiments, the activator is a tumor cell with a ligand (e.g., ULBP and MICA / B) that can be recognized by receptors (e.g., NKG2D, NKp46, NKp30, and DNAM-1) on NK cells or modified cells. This interaction activates NK cells, which cause tumor cells to lyse. In some embodiments, the tumor cell that activates NK cells or modified cells is a K562 cell.
[0046] NK cells or modified cells can also be activated by contact with one or more activators containing antibodies and their target cells. The Fc receptor CD16 expressed on NK cells or modified cells recognizes and interacts with the Fc fragment of the target-bound antibody, and this interaction activates NK cells to lyse the target cell, a process known as ADCC.
[0047] The term “expression” refers to the production of a gene product. When referring to expression, the term “stable” means that the polynucleotide is integrated into the cell’s genome and expressed.
[0048] As used herein, the term “antibody” refers to an immunoglobulin or a fragment thereof. Antibodies can be of any type (e.g., IgG, IgA, IgM, IgE, or IgD). Preferably, the antibody is IgG. Antibodies can be non-human (e.g., derived from mice, goats, or any other animal), fully human, humanized, or chimeric. Antibodies can be polyclonal or monoclonal. Optionally, the antibody is monoclonal.
[0049] As used herein, the term “cancer” refers to all types of cancer, growths, or malignancies found in mammals, including leukemia, carcinoma, and sarcoma. Exemplary cancers include brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer,Liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, gastric cancer, uterine cancer, and medulloblastoma. Other examples include Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, essential thrombocytosis, essential macroglobulinemia, primary brain tumor, cancer, malignant pancreatic islets, malignant carcinoid tumors, bladder cancer, precancerous skin lesions, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, urogenital tract cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, tumors of endocrine and exocrine glands, and prostate cancer.
[0050] Cells
[0051] Cell lines are unique cell lines found to proliferate in the presence of interleukin-2 (IL-2). Gong et al., Leukemia 8:652-658 (1994). These cells have high cytolytic activity against a variety of cancers. The cells are a population of homologous cancerous NK cells with broad antitumor cytotoxicity and predictable results after expansion. Their safety profile has been confirmed in a phase I clinical trial. They were found in the blood of subjects with non-Hodgkin lymphoma and then immortalized in vitro. The cells are derived from NK cells but lack the major inhibitory receptors present on normal NK cells, while retaining most of the activating receptors. However, the cells do not attack normal cells and do not elicit an unacceptable immune rejection response in humans. Characterization of the cell line is disclosed in WO 1998 / 49268 and U.S. Patent Application Publication No. 2002-0068044.
[0052] The cell line was found to present surface markers of CD56bright, CD2, CD7, CD11a, CD28, CD45, and CD54. Furthermore, it did not exhibit markers for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, and CD34. Cell growth in culture depended on the presence of recombinant interleukin-2 (rIL-2), with doses as low as 1 IU / mL sufficient to maintain proliferation. IL-7 and IL-12 did not support long-term growth, nor did other tested cytokines, including IL-1α, IL-6, tumor necrosis factor-α, interferon-α, and interferon-γ. High cytotoxicity was observed even at a low effector-to-target (E:T) ratio of 1:1. Gong et al., ibid. Cells were deposited at the American Type Culture Collection (ATCC) and named CRL-2407.
[0053] Although the cells retained almost all activating receptors and cell lysis pathways associated with NK cells, they did not express CD16 on their cell surface. CD16 is an antibody that recognizes and binds to the Fc moiety of antibodies to activate NK cells.Fc receptors for ADCC. Due to the absence of CD16 receptors, cells cannot lyse target cells via ADCC mechanisms and therefore cannot enhance the antitumor effects of endogenous or exogenous antibodies (i.e., rituximab and Herceptin).
[0054] Studies on endogenous NK cells have shown that IL-2 (1000 IU / mL) is crucial for NK cell activation during transport, but cells do not need to be maintained at 37°C and 5% carbon dioxide. Koepsell et al., Transfusion 53:398-403 (2013). However, endogenous NK cells differ significantly from NK cells, largely due to their distinctly different origins: NK cells are derived from cancer cell lines, while endogenous NK cells are harvested from donors (or patients) and processed for infusion into patients. Endogenous NK cell preparations are heterogeneous cell populations, while NK cells are homogeneous clonal cell lines. NK cells readily proliferate in culture while maintaining cytotoxicity, whereas endogenous NK cells do not. In addition, the heterogeneous population of endogenous NK cells does not aggregate at high density. Furthermore, endogenous NK cells express Fc receptors, including the CD-16 receptor which is not expressed by the cells.
[0055] Generation of IL2-dependent cells
[0056] The IL2-dependent cells disclosed in this application are cells modified by introducing a high-affinity Fc γ receptor (Fc γ RIIIa / CD16a) gene. This form of CD16 has a valine residue at amino acid 176, which has a high affinity for the Fc fragment of the antibody and thus promotes the enhancement of ADCC. Specification 8 / 34 pages 11 CN 121518401 A
[0057] The CD16 transgene can be engineered into an expression vector by any mechanism known to those skilled in the art. In some embodiments, the vector allows the transgene to be integrated into the genome of the cell. In some embodiments, the vector has a positive selection marker. The positive selection marker includes any gene that allows the cells to grow under conditions that kill cells that do not express the gene. Non-limiting examples include antibiotic resistance, such as genimycin (from the Neo gene of Tn5).
[0058] A variety of vectors can be used to express the Fc receptor disclosed herein. In some embodiments, the vector is a plasmid. In one embodiment, the vector is a viral vector. Viral vectors include, but are not limited to, lentiviral vectors, retroviral vectors, adenovirus vectors, adeno-associated virus vectors, herpes simplex virus vectors, poxvirus vectors, etc.
[0059] The transgene can be introduced into cells using any transfection method known in the art, including but not limited to infection, electroporation, lipid transfection, nuclear transfection, or the "gene gun method".
[0060] In some embodiments, the CD16 transgene is introduced into cells via lentivirus. Typically, it contains...The CD16 transgenic viral construct is first introduced into a cell line along with other plasmids required for packaging lentivirus. These plasmids may include at least one lentiviral packaging plasmid, such as pCMV-ΔR8.2, and an envelope plasmid, such as pCMV-VSV-G. After transfection, viral particles are formed in the culture supernatant. The supernatant is collected and used to infect cells to produce IL2-dependent cells expressing CD16. In some embodiments, cells expressing CD16 are enriched prior to plating by limiting dilution. Individual clones of cells expressing CD16 can then be selected for amplification, and then phenotypic and functional analyses are performed.
[0061] Thus, this disclosure provides a population of modified cells (i.e., IL2-dependent cells) expressing CD16 (SEQ ID NO: 1), wherein the modified cells do not express IL-2, and wherein the population comprises one or more modified cells. In some embodiments, the modified cells contain the nucleic acid of CD16 (SEQ ID NO: 2). In some embodiments, the modified cells have antibody-dependent cell-mediated cytotoxicity (ADCC).
[0062] Another type of cell, haNK003 cells, is generated by electroporation-stable transfection of cells with a bicistronic plasmid-based vector containing sequences encoding CD16 (SEQ ID NO: 1) and IL-2 (SEQ ID NO: 3). A method for generating haNK003 is disclosed in application number 62 / 468,890, the entire contents of which are incorporated herein by reference.
[0063] Measurement of CD16 expression on IL2-dependent cells
[0064] Unlike NK cells that lose CD16 expression upon activation, the IL2-dependent cells provided in this disclosure are able to maintain high levels of CD16 expression during and / or after activation. Generally, despite the lack of IL-2 expression, IL2-dependent cells maintain high levels of CD16 expression, indicating that IL-2 expression has no adverse effect on the CD16 stability of cells.
[0065] The level of CD16 expression on cells (e.g., IL2-dependent haNK cells) can be measured by any method known in the art for measuring protein expression (e.g., immunoblotting, ELISA, and flow cytometry). In some embodiments, CD16 expression is measured by flow cytometry. Detection of CD16 expression by flow cytometry typically involves incubating a cell sample with an anti-CD16 antibody conjugated to a fluorescent dye. The sample is then analyzed on a flow cytometer to detect the bound antibody, and the intensity of the fluorescent dye from the bound antibody, such as the mean fluorescence intensity, corresponds to the amount of CD16 expressed on the cells.
[0066] In some embodiments, cells are activated by incubation with PMA and iomycin, for example, IL2. (Specification 9 / 34 pages 12 CN)121518401 A-dependent cells, and measuring CD16 expression levels before and after activation. In some embodiments, incubation lasts 0.5–4 hours, for example 0.5–2 hours, or about 1 hour. In some embodiments, the PMA used to activate cells is 10–80 nM, for example 20–60 nM, or about 40 nM. In some embodiments, the ionomycin used to activate haNK™ cells is 200–1000 nM, for example 300–800 nM, 400–700 nM, or about 669 nM. In some embodiments, the CD16 expression level on haNK™ cells is reduced by no more than 20% compared to the CD16 expression level on cells before activation, for example no more than 40%, no more than 30%, or no more than 25%. In some embodiments, the percentage of CD16-positive cells after activation is reduced by no more than 20% or no more than 18% compared to the cells before activation. In some embodiments, the percentage of CD16-positive cells after activation is not reduced. In some embodiments, activated cells (e.g., IL-2-dependent cells) exhibit a reduction in CD16 expression in the range of 0-20%, 0-10%, or 0-5% compared to pre-activation CD16 expression levels.
[0067] In some embodiments, cells can be activated by co-culturing them with target cells sensitive to NK cells (e.g., tumor cells), such as IL-2-dependent cells. In some embodiments, the tumor cells are K562 cells. K562 cells are human chronic myeloid leukemia cells. As used in this disclosure, the effector-target ratio refers to the number of effector cells (e.g., cells, including IL-2-dependent cells) relative to the number of target cells. In some embodiments, the effector-target ratio is between 0.5:1 and 2:1, for example, about 1:1. The length of the incubation period is generally sufficient to achieve complete cytotoxic killing of the target cells. In some embodiments, the incubation period is about 2 to 8 hours, for example, about 4 hours. In some embodiments, after the incubation period, the cells are allowed to recover in the culture medium. In some embodiments, the recovery period lasts 12–48 hours, for example, about 20–28 hours or about 24 hours. In some embodiments, i) CD16 expression levels on cells are monitored before and ii) at the end of the incubation period and / or the end of the recovery period. In some embodiments, compared with pre-activation cells, CD16 expression in the cell population decreases by no more than 20%, no more than 10%, no more than 5%, and no more than 3% after contact with target cells (e.g., at the end of the incubation period or the end of the recovery period). In some embodiments, compared with cells before contact with target cells, the percentage of CD16-positive cells decreases by no more than 20% and no more than 10% at the end of the incubation period or the end of the recovery period.
[0068] In some embodiments, cells may also be activated by contact with the antibody and its target cells, wherein contact leads to ADCC. In some embodiments, the antibody is rituximab (anti-CD20 antibody), and the target cells are DOHH-2 cells. In some embodiments, the antibody is Herceptin (anti-HER2 antibody), and the target cells are SKBR3 cells. In some embodiments, the effector-target ratio is in the range of 1:1 to 1:10, for example, 1:1, 1:2, or 1:4. In some embodiments, CD16 expression in cells (e.g., IL2-dependent cells) after ADCC is reduced by no more than 50% compared to haNK003 cells before ADCC, for example, no more than 40%, no more than 30%, no more than 25%, no more than 20%, or no more than 10%. In some embodiments, the percentage of cells in the CD16-positive population (e.g., IL2-dependent cells) is reduced by no more than 20% or no more than 10% compared to cells in the population before ADCC.
[0069] Therefore, this disclosure also provides a method for generating a modified cell population capable of maintaining CD16 expression during activation, wherein the method includes introducing CD16 (SEQ ID NO: 2) instead of IL-2 into the cells, wherein CD16 expression on the activated modified cells is not less than 50% of CD16 expression on the pre-activated modified cells. Specification 10 / 34 pages 13 CN 121518401 A
[0070] In some embodiments, the activated cells (e.g., IL-2-dependent cells) maintain a steady state of cytotoxicity for at least 24 hours from the start of activation. The cytotoxicity of the cells can be measured using methods known in the art. In some embodiments, the cytotoxicity is direct cytotoxicity. In some embodiments, the cytotoxicity is ADCC. Maintaining a steady state of cytotoxicity over a period of time means that the ability of the cells to lyse target cells remains substantially the same over a reference time period. In some cases, maintaining cytotoxic homeostasis is reflected as, under the same assay conditions, the percentage of target cells lysed by effector cells at the end of the reference time period being at least 70%, such as at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, of the percentage of target cells lysed by effector cells at the beginning of the reference time period.
[0071] Additional transgenes
[0072] In some embodiments, the modified cells, such as IL2-dependent cells, are further engineered to express chimeric antigen receptors (CARs) on the cell surface. Optionally, the CAR is specific to tumor-specific antigens. Non-limiting provisions are made in US2013 / 0189268; WO1999024566A1; US 7098008 and WO 2000020460 A1.Tumor-specific antigens are described in an illustrative manner; each is incorporated herein by reference in its entirety. Tumor-specific antigens include, but are not limited to, NKG2D, CS1, GD2, CD138, EpCAM, EBNA3C, GPA7, CD244, CA-125, ETA, MAGE, CAGE, BAGE, HAGE, LAGE, PAGE, NY-SEO-1, GAGE, CEA, CD52, CD30, MUC5AC, c-Met, EGFR, FAB, WT-1, PSMA, NY-ESO1, AFP, CEA, CTAG1B, CD19, and CD33. Other non-restricted tumor-associated antigens and associated malignancies are listed in Table 1.
[0073] Table 1: Tumor-specific antigens and related malignancies, 11 / 34 pages, 14 CN 121518401 A
[0074] 12 / 34 pages, 15 CN 121518401 A
[0075] 13 / 34 pages, 16 CN 121518401 A
[0076]
[0077] In some embodiments, the CAR targets CD19, CD33, or PD-L1.
[0078] In examples, variant peptides are prepared using methods known in the art, such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter, 1986; Zoller and Smith, 1987), cassette mutagenesis, restriction-selective mutagenesis (Wells et al., 1985) or other known techniques can be used to produce CD16 variants from cloned DNA (Ausubel, 2002; Sambrook and Russell, 2001).
[0079] Optionally, CAR targets an antigen associated with a specific cancer type. Optionally, the cancer is selected from leukemia (including acute leukemia (e.g., acute lymphoblastic leukemia, acute myeloid leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemia (e.g., chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström macroglobulinemia, heavy chain disease, and solid tumors, including but not limited to sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteoblastic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, etc. Colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland cancer, sebaceous gland cancerCancer, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, nephroblastoma, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningeal hemangioma, melanoma, neuroblastoma, and retinoblastoma.
[0080] In some embodiments, the polynucleotide encoding the CAR is mutated to change the amino acid sequence encoding the CAR without changing the function of the CAR. For example, a polynucleotide substitution resulting in an amino acid substitution at a "non-essential" amino acid residue can be made in the CAR disclosed above. CARs can be engineered as described, for example, in patent publications WO 2014039523; US20140242701; US20140274909; US20130280285 and WO 2014099671, each of which is incorporated herein by reference in its entirety. Optionally, the CAR is a CD19 CAR, CD33 CAR, or CSPG-4 CAR.
[0081] Additional Modifications – Suicide Genes
[0082] In some embodiments, modified cells, such as IL2-dependent cells, are further engineered to introduce a suicide gene. The term “suicide gene” is a gene that allows negative selection of cells. The suicide gene specification 14 / 34 pages 17 CN 121518401 A is used as a safety system that allows cells expressing the gene to be killed by the introduction of a selection agent. This is needed in cases where recombinant genes cause mutations that lead to uncontrolled cell growth. Several suicide gene systems have been identified, including the herpes simplex virus thymidine kinase (TK) gene, cytosine deaminase gene, varicella-zoster virus thymidine kinase gene, nitroreductase gene, Escherichia coli gpt gene, and Escherichia coli Deo gene (see also, e.g., Yazawa K, Fisher WE, Brunicati FC: Current progress in suicide gene therapy for cancer. World J. Surg. 2002 July; 26(7): 783-9). As used herein, suicide genes are active in cells. Typically, the proteins encoded by suicide genes have no adverse effects on cells, but kill cells in the presence of certain compounds. Therefore, suicide genes are often part of a system.
[0083] In one embodiment, the suicide gene is the thymidine kinase (TK) gene. The TK gene can be a wild-type or mutant TK gene (e.g., tk30, tk75, sr39tk). Cells expressing the TK protein can be killed with ganciclovir.
[0084] In another embodiment, the suicide gene is a cytosine deaminase, which is cytotoxic in the presence of 5-fluorocytosine. Garcia-Sanchez et al., "Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation." Bood 1998 Jul 15; 92(2): 672-82.
[0085] In another embodiment, the suicide gene is cytochrome P450, which is toxic in the presence of ifosfamide or cyclophosphamide. See, for example, Touati et al., "A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response." Curr Gene Ther. 2014; 14(3): 236-46.
[0086] In another embodiment, the suicide gene is iCas9. Di Stasi, (2011) "Inducible apoptosis as a safety switch for adoptive cell therapy." N Engl J Med 365: 1673-1683. See also Morgan, "Live and Let Die: A New Suicide Gene Therapy Moves to the Clinic" Molecular Therapy (2012); 20: 11-13. The iCas9 protein induces apoptosis in the presence of the small molecule AP1903. AP1903 is a biologically inert small molecule that has shown good tolerability in clinical studies and has been used in adoptive cell therapy.
[0087] Similar to the CD19 transgene disclosed above, these additional transgenes (e.g., CD19CAR) can be engineered into expression vectors by any mechanism known to those skilled in the art. These additional transgenes can be engineered into the same expression vector as the CD19 transgene or into different expression vectors. In a preferred embodiment, the transgene is engineered into the same expression vector as the CD19 transgene.In the vector.
[0088] Treatment methods using IL2-dependent cells
[0089] Methods of treating a subject with modified cells (e.g., IL2-dependent cells described herein) are also provided. Optionally, the subject is treated with modified cells and an antibody.
[0090] Modified cells, such as IL2-dependent cells, can be administered to the subject in absolute numbers of cells, for example, the subject can be administered about 1,000 cells / injection to up to about 10 billion cells / injection, for example, about, at least about or at most about 1×10¹⁰, 1×10⁹, 1×10⁸, 1×10⁷, 5×10⁷, 1×10⁶, 5×10⁶, 1×10⁵, 5×10⁵, 1×10⁴, 5×10⁴, 1×10³, 5×10³ (etc.) modified cells, such as IL2-dependent cells / injection, or any range between any two numbers (including the endpoints). Optionally, the subject is administered 1×10⁸ to 1×10¹⁰ cells. Optionally, cells are administered once or more weekly for one or more weeks. Optionally, cells are administered once or twice weekly for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 weeks or more.
[0091] Optionally, the subject is administered approximately 1,000 cells / injection / m2 to up to approximately 10 billion cells / injection / m2, such as approximately, at least approximately or at most approximately 1×10⁸ / m2, 1×10⁷ / m2, 5×10⁷ / m2, 1×10⁶ / m2, 5×10⁶ / m2, 1×10⁵ / m2, 5×10⁵ / m2, 1×10⁴ / m2, 5×10⁴ / m2, 1×10³ / m2, 5×10³ / m2 (etc.) modified cells, such as IL2-dependent cells / injection, or any range between any two numbers (including the endpoints).
[0092] Optionally, modified cells, such as IL2-dependent cells, may be administered to such an individual in a relative number of cells, for example, the individual may be administered about 1,000 cells to up to about 10 billion cells / kg individual, for example about, at least about or at most about 1×10⁸, 1×10⁷, 5×10⁷, 1×10⁶, 5×10⁶, 1×10⁵, 5×10⁵, 1×10⁴, 5×10⁴, 1×10³, 5×10³ (etc.) modified cells, such as IL2-dependent cells / kg individual, or any range between any two numbers (including the endpoints).
[0093] Optionally, the total dose may be calculated in m² of body surface area, including about 1×10¹¹, 1×10¹⁰, 1×10⁹, 1×10⁸, 1×10⁷ / m², or any range between any two values (including the endpoints). Optionally, approximately 1 billion to 3 billion modified [products] may be administered to the patient.Cells, such as IL2-dependent cells. Optionally, the amount of modified cells (e.g., IL2-dependent cells) injected per dose may be calculated in m2 of body surface area, including 1×10¹¹, 1×10¹⁰, 1×10⁹, 1×10⁸, 1×10⁷ / m².
[0094] The modified cells (e.g., IL2-dependent cells) and optionally other anticancer agents may be administered to the cancer patient once, or multiple times, for example, every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 hours during treatment, or every 1, 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 weeks or more, or any range between any two values (including the endpoints).
[0095] In one embodiment, the modified cells, such as IL2-dependent cells, are irradiated before being administered to a patient. For example, the irradiation of modified cells (e.g., IL2-dependent cells) is described in U.S. Patent No. 8,034,332, which is incorporated herein by reference in its entirety. In one embodiment, modified cells, such as IL2-dependent cells, that are not engineered to express a suicide gene are irradiated.
[0096] Optionally, the modified cells (e.g., IL2-dependent cells) are administered in a composition comprising the modified cells (e.g., IL2-dependent cells) and a medium (e.g., human serum or its equivalent). Optionally, the medium comprises human serum albumin. Optionally, the medium comprises human plasma. Optionally, the medium comprises about 1% to about 15% human serum or human serum equivalent. Optionally, the medium comprises about 1% to about 10% human serum or human serum equivalent. Optionally, the medium comprises about 1% to about 5% human serum or human serum equivalent. Optionally, the medium comprises about 2.5% human serum or a human serum equivalent. Optionally, the serum is human AB serum. Optionally, a serum substitute acceptable for use in human therapeutics is used instead of human serum. Such serum substitutes may be known in the art. Optionally, the modified cells (e.g., IL2-dependent cells) are administered in a composition comprising the modified cells (e.g., IL2-dependent cells) and an isotonic fluid solution supporting cell viability. Optionally, the modified cells (e.g., IL2-dependent cells) are administered in a composition reconstituted from a cryopreserved sample. Specification 16 / 34 pages 19 CN 121518401 A
[0097] According to the methods provided herein, a subject is administered an effective amount of one or more of the pharmaceutical agents provided herein. The terms effective amount and effective dose are used interchangeably. The term effective amount is defined as the amount required to produce the desired physiological response (e.g., reduction of inflammation).Any amount. The effective amount and schedule for administering the medication can be determined by those skilled in the art based on experience. The range of doses used for administration is those that are large enough to produce the desired effect in which one or more symptoms of the disease or disorder are affected (e.g., reduced or delayed). The dose should not be so large as to cause substantial adverse reactions, such as unwanted cross-reactions, allergic reactions, etc. Generally, the dose varies with age, condition, sex, type of disease, degree of disease or disorder, route of administration, or whether other medications are included in the regimen, and can be determined by those skilled in the art. In the event of any contraindications, the individual physician may adjust the dose. The dose may be varied and may be administered daily at one or more doses for one or more days. Guidance on appropriate doses for a given class of medicines can be found in the literature. For example, for a given parameter, the effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Efficacy may also be expressed as an increase or decrease in "multiples". For example, the therapeutically effective dose may have at least 1.2, 1.5, 2, 5, or higher efficacy compared to the control. The precise dosage and formulation depend on the therapeutic purpose and are determined by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Remington: The Science and Practice of Pharmacy, 22nd Edition, Gennaro, Editor (2012); and Pickar, Dosage Calculations (1999)).
[0098] Pharmaceutically acceptable compositions may include a variety of carriers and excipients. A variety of aqueous carriers may be used, such as buffered saline solutions. These solutions are sterile and generally do not contain unwanted substances. Suitable carriers and excipients, and their formulations, are described in Remington: The Science and Practice of Pharmacy, 21st Edition, David B. Troy, ed., Lippicott Williams & Wilkins (2005). A pharmaceutically acceptable carrier is a material that is not biologically or otherwise undesirable, meaning that the material, when administered to a subject, will not cause undesirable biological effects or interact harmfully with other components of a pharmaceutical composition containing that material. If administered to a subject, the carrier...Optionally, the formulation may be selected to minimize degradation of the active ingredient and to minimize adverse side effects in the subject. As used herein, the term “pharmaceuticalally acceptable” is used synonymously with “physiologically acceptable” and “pharmacologically acceptable.” Depending on the route of administration, pharmaceutical compositions typically contain agents for buffering and preservation during storage and may include buffers and carriers for appropriate delivery.
[0099] The composition may contain acceptable excipients required to approximate physiological conditions, such as pH adjusters and buffers, toxicity modifiers, etc., such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentrations of cells and / or other agents in these formulations may vary and are selected primarily based on fluid volume, viscosity, body weight, etc., according to the specific administration modality chosen and the needs of the subject.
[0100] Optionally, modified cells (e.g., IL2-dependent cells) are administered to the subject in combination with one or more other treatments for the cancer being treated. Unbound by theory, it is believed that co-treatment of a subject with modified cells (e.g., IL2-dependent cells) and another cancer therapy allows the modified cells (e.g., IL2-dependent cells) and the alternative therapy to give the endogenous immune system the ability to clear cancers that have previously overwhelmed the endogenous effect. Optionally, two or more other treatments for the cancer being treated include, for example, antibodies, radiation, chemotherapy, stem cell transplantation, or hormone therapy.
[0101] Optionally, the antibody is administered to the patient in combination with the modified cells (e.g., IL2-dependent haNK cells). Optionally, the modified cells (e.g., IL2-dependent cells) and the antibody are administered together (e.g., in the same formulation as in the specification, page 17 / 34, 20 CN 121518401 A); simultaneously to the subject, alone (e.g., in a separate formulation); or may be administered alone, for example, according to a different dosing regimen or at a different time of day. When administered alone, the antibody may be administered via any suitable route, such as intravenous or oral administration.
[0102] Optionally, antibodies can be used to target cancer cells or cells expressing cancer-related biomarkers. Many antibodies have been approved for use alone to treat cancer.
[0103] Table 2. Examples of FDA-approved therapeutic monoclonal antibodies
[0104] Specification 18 / 34 pages 21 CN 121518401 A
[0105]
[0106] Antibodies can treat cancer through a variety of mechanisms. ADCC occurs when immune cells (such as NK cells) bind to antibodies that bind to target cells via Fc receptors (such as CD16).
[0107] Thus, cells expressing CD16 can be used with an effective amount of at least one specific cancer-related protein. Specification 19 / 34 pages 22 CN 121518401 AMonoclonal antibodies are administered to the subject together, such as alemtuzumab, bevacizumab, teimozumab, ofamumab, rituximab, and trastuzumab. Optionally, the monoclonal antibody is a naked monoclonal antibody, a conjugated monoclonal antibody, or a bispecific monoclonal antibody. Optionally, a bispecific antibody that binds to cancer cells and also to cell surface proteins present on the cell surface can be used.
[0108] Cancer-specific antibodies bind to specific protein antigens expressed on the surface of cancer cells. Cells can be modified such that the antibody binds to the cell surface. Optionally, the antibody is cancer-specific. In this way, cells can specifically target cancer. Neutralizing antibodies can also be isolated. For example, the secreted glycoprotein YKL-40 is elevated in many types of advanced human cancers. Anti-YKL-40 antibodies are envisioned to be used to inhibit tumor growth, angiogenesis, and / or metastasis. See Faibish et al., (2011) Mol. Cancer Ther. 10(5): 742-751.
[0109] Antibodies against cancer can be purchased from commercially available sources or can be generated by any method known in the art. For example, antibodies can be generated by obtaining B cells, bone marrow, or other samples from one or more patients who were previously infected with cancer and have recovered or are recovering at the time of sampling. Methods for identifying, screening, and growing antibodies (e.g., monoclonal antibodies) from these samples are known. For example, a phage display library can be prepared by isolating RNA from a target sample or cells, preparing cDNA from the isolated RNA, enriching the cDNA against the heavy chain and / or light chain cDNA, and creating a library using a phage display vector. For example, libraries can be prepared and screened as described in Maruyama et al., which is incorporated herein by reference in its entirety. Antibodies can be prepared by recombinant methods or any other method. The isolation, screening, characterization, and generation of human monoclonal antibodies are also described in Beerli et al., PNAS (2008) 105(38): 14336-14341, which is incorporated herein by reference in its entirety.
[0110] Combinations of pharmaceutical agents or compositions may be administered concurrently (e.g., as a mixture), alone but simultaneously (e.g., via a separate intravenous line), or sequentially (e.g., administering one agent first, followed by a second agent). Therefore, the term combination is used to refer to the concurrent, simultaneous, or sequential administration of two or more pharmaceutical agents or compositions. The treatment process is preferably determined on an individual basis, depending on the specific characteristics of the subject and the type of treatment chosen. Treatments (e.g., those disclosed herein) may be administered to the subject daily, twice daily, every two weeks, monthly, or in any applicable manner in which treatment is effective. Treatments may be administered alone or in combination with any other treatment disclosed herein or known in the art. Additional treatments may be administered concurrently with the first treatment, at different times, or according to entirely different treatment regimens (e.g., the first treatment may be administered daily, while the second...).(External treatment is administered weekly).
[0111] Kit
[0112] A kit containing the provided IL2-dependent cells is also disclosed. Optionally, the kit further includes one or more additional agents, such as antibodies. The components of the kit may be contained in one or different containers, such as one or more vials. The antibody may be in liquid or solid form (e.g., after freeze-drying) to increase shelf life. If in liquid form, the components may contain additives (such as stabilizers and / or preservatives (such as proline, glycine, or sucrose) or other additives to increase shelf life).
[0113] Optionally, the kit may contain additional compounds, such as therapeutically active compounds or drugs administered before, simultaneously with, or after the administration of IL2-dependent cells and antibodies. Examples of such compounds include vitamins, minerals, hydrocortisone, ibuprofen, lidocaine, quinidine, chemotherapeutic agents, etc.
[0114] Optionally, the instructions for use of the kit include instructions for using the kit components in cancer treatment. The specification may also contain information on how to prepare (e.g., in the case of lyophilized proteins, dilution or reconstruction) antibodies and IL2-dependent cells (e.g., thawing and / or culturing). The specification may also include instructions on dosage and frequency of administration. Specification 20 / 34 pages 23 CN 121518401 A
[0115] Materials, compositions and components that can be used in the disclosed methods and compositions, materials that can be used in conjunction with the disclosed methods and compositions, materials that can be used to prepare the disclosed methods and compositions or as products of the disclosed methods and compositions are disclosed. These and other materials are disclosed herein, and it should be understood that when combinations, subsets, interactions, groups, etc., of these materials are disclosed, each of them is specifically considered and described herein, although specific references to the various individual and collective combinations and arrangements of these compounds may not be explicitly disclosed. For example, if a method is disclosed and discussed, and various modifications that can be made to multiple molecules including the method are discussed, then various and every combination and arrangement of the method and possible modifications are specifically considered, unless the opposite is specifically indicated. Similarly, any subset or combination of these is also specifically considered and disclosed. This concept applies to all aspects of this disclosure, including but not limited to steps in methods using the disclosed compositions. Therefore, if multiple additional steps are available, it should be understood that each of these additional steps can be performed by any particular method step or combination of method steps of the disclosed method, and each such combination or subset of combinations is specifically considered and should be considered disclosed.
[0116] Publications cited herein and the material referenced therein are specifically incorporated herein by reference in their entirety.
[0117] The following examples are intended to further illustrate certain aspects of the methods and compositions described herein, and are not intended to limit the scope of the claims.
[0118] Example
[0119] Example 1. Materials
[0120] The cellular fluorescence analysis of the cell surface proteins described in this example was performed using direct immunostaining with specific fluorophore-conjugated antibodies or the corresponding isotype controls listed in the table above. Briefly, 10e⁵ cells were stained with the manufacturer-recommended amount of antibody for 30 minutes in 100 μL of flow cytometry staining buffer (PBS, 1% BSA) at 4°C in the dark. Cells were washed twice with flow cytometry staining buffer and resuspended in 200 μL of flow cytometry staining buffer. Samples were processed on a 10 flow cytometer (Miltenyi Biotec) and data were analyzed using FlowJo software. The antibodies used in the examples are shown in Table 3:
[0121] Table 3. Antibodies
[0122]
[0123]
[0124] Example 2. Generation of IL2-dependent haNK cells
[0125] IL2-dependent cells were generated by genetically modifying aNK™ cells by stably transfecting them with the pCL20c-V176-CD16 lentiviral construct. This construct encodes a CD16 sequence with valine at amino acid 176 (calculated from the start codon 24 CN 121518401 A on page 21 / 34 of the full-length protein specification), instead of phenylalanine in the natural CD16 polypeptide, which increases ADCC.
[0126] The pCL20c-V176-CD16 construct was generated based on pCL20c-Mp-CD19CAR-IRES-GFP (SEQ ID NO: 6), which is 8928 bp and contains CD19-CAR at positions 2917-4380 bp, IRES at positions 4381-4980 bp, and GFP at positions 4981-5700 bp. The plasmid was digested with KpnI, which cut at positions 2906, 4852, and 5729 to remove CD19-CAR and GFP. Restriction digestion yielded three fragments of the following sizes: 6015 (backbone), 1946, and 877 bp. The backbone fragments were purified, and a double-stranded oligomer containing the top strand (SEQ ID NO: 7) and the bottom strand (SEQ ID NO: 8) was ligated to the backbone generated above. The addition of this oligonucleotide introduced EcoRI, SphI, and NotI sites, which are non-cutter variants in the CD16 sequence. The CD16 gene was cloned using PCR primers SEQ ID NO: 9 and SEQ ID NO: 10. The amplified CD16 polynucleotide contained KpnI and NotI sites at the ends and was cloned into an engineered backbone fragment by digesting the backbone and amplified CD16 with these two enzymes and then ligating them. The full nucleotide sequence of the pCL20c-V176-CD16 plasmid is shown in SEQ ID NO: 11.
[0127] In summary, the pCL20c-V176-CD16 lentiviral seed was subsequently produced by transfecting 7 x 10e6 293T cells per 10 cm Piper dish with the following amounts of plasmids: 7.5 μg pCL20c-V176-CD16, 5 μg pCMV-ΔR8.2, and 2.5 μg pCMV-VSV.G. The latter two plasmids are described in Naldini et al., Science Apr. 12; 272(5259): 263-7 (1996) and Zufferey et al., Nat. Biotechnol. 1997 Sep; 15(9): 871-5. Transfection was performed using Lipofectamine 3000 (Life Technologies, catalog #L3000-008) according to the manufacturer's instructions. Viral supernatant was collected 48 hours post-transfection and concentrated 10-fold using PEG-it virus precipitation solution (catalog number LV810A-1) from System Biosciences. 5 x 10e⁵ aNK™ cells were infected with 100 μl of concentrated virus in 1 ml of final medium in 24-well plates via rotation culture (840 g, 35°C for 99 min) in the presence of TransDux (System Biosciences, catalog number LV850A-1). V176-CD16-expressing cells were enriched using purified anti-human CD16 antibody (BioLegend, catalog number 302002) and anti-mouse IgG MicroBeads (catalog number 130-048-401) from Miltenyi, according to the manufacturer's instructions. Following enrichment, cells were plated using limiting dilutions. After growing for 15 days in X-VIVO 10 medium supplemented with 5% heat-inactivated human AB serum and 500 IU / mL IL-2, single clones H2, H7, and H20 (“H clones”) and P74, P82, and P110 (“P clones”) were selected. CD16 expression in the cells was tested by flow cytometry using an antibody against CD16 conjugated to APC-Cy7 (BioLegend, catalog #302018). CD16 expression in these single clones during the 24-week growth period post-infection was monitored by flow cytometry, and the results are shown in Figure 4.
[0128] Example 3. Generation of haNK003 cells
[0129] haNK003 cells were generated by electroporating aNKTM cells with a bicistronic plasmid vector containing sequences of both CD16 and IL-2. The IL-2 sequence is labeled with the endoplasmic reticulum retention signal KDEL to prevent the secretion of the IL-2 protein from the endoplasmic reticulum (ER), and is referred to as ER IL-2, having the amino acid sequence of SEQ ID NO: 3. The polynucleotide encoding the IL-2 labeled with the endoplasmic reticulum retention signal has SEQ ID NO: 3.The nucleotide sequence of NO: 4.
[0130] Transfection plasmid
[0131] The plasmid was constructed by GeneArt AG according to the provided specifications. The synthetic gene pNEUKv1_FcRIL2 (SEQ ID NO: 5) was assembled from synthetic oligonucleotides and PCR products. The fragment was cloned into the backbone of the pNEUKv1_O059 vector using EcoRI and NotI restriction sites. pNEUKv1_O059 is a synthetic vector containing an ampicillin resistance cassette. The promoter used to express the transgene was EF-1α with the SV40 polyadenylated sequence. The resulting plasmid was 5,491 base pairs (bp) long and contained human sequences of CD16 and IL-2. Neither CD16 nor IL-2 had any transforming properties. The plasmid DNA was purified from the transformed bacteria and its concentration was determined by UV spectroscopy. The final construct was verified by sequencing. The sequence congruence within the restriction sites used was 100%. The plasmid was prepared under TSE-free production conditions. See instruction manual, pages 22 / 34, 25 CN 121518401 A
[0132] The full nucleotide sequence of the pNEUKv1_FcRIL2 plasmid is shown in SEQ ID NO: 5.
[0133] To generate the haNK003 cell line, vials of (aNK™) Master Cell BaNK™ (MCB) (aNK™ COA) and 250 mg of pNEUKv1_FcRIL2 plasmid were sent to EUFETS GmbH. EUFETS thawed the MCB vials and cultured the cells to a sufficient number for plasmid transfection. For the first two days after transfection, the transfected cells were grown in a medium containing IL-2, X-VIVO 10, and 5% heat-inactivated human AB serum. After two days, no more IL-2 was added to the growth medium, and any transfected cells producing sufficient amounts of IL-2 continued to grow. Multiple clones were isolated by limiting dilution, and phenotype and Fc receptor expression were preliminarily screened. Six (6) clones exhibiting good viability (>70%), acceptable doubling time, expected phenotype, and positive Fc receptor expression were sent to the German Red Cross GMP Testing Laboratory (GRC) for further screening and final selection of a single clone. At the GRC, the phenotype (including Fc receptor expression), ADCC, cytokine profile, growth characteristics, and radiosensitivity of all clones were tested. The selected cell line haNK003 was used to generate the master cell library.
[0134] Whole-genome sequencing of the selected clones confirmed that the plasmid insertion site was located at a single position at positions 15,654,977–15,661,403 on chromosome 17.
[0135] Multiple clones generated by aNK™ cell electroporation were selected by a round of limiting dilution. A single clone was used to establish the GMP master cell library haNK003.
[0136] Example 4. Evaluation of CD16 expression on IL2-dependent cells after PMA / Isomycin activation
[0137] haNK003 cells and IL2-dependent cells generated as described above, as well as NK cells from three donors (#5, #7, and #8), were incubated with 40 nM PMA and 669 nM iomycin for 1 hour. CD16 expression was monitored by incubating pre-stimulation and post-stimulation cells with antibodies conjugated to a CD16-specific fluorescent dye and detecting the bound antibodies by flow cytometry. Table 4 summarizes the percentage of cells expressing CD16, and a representative graphical representation is shown in Figure 1A (before PMA stimulation) and Figure 1B (after PMA stimulation).
[0138] Table 4. CD16 expression after PMA / Ionicin activation
[0139]
[0140] The results showed that PMA / Ionicin treatment led to a 90% ± 0.06% downregulation of CD16 expression in donor NK cells, while the treatment only led to a 25.5% ± 0.04% downregulation in haNK003 cells and haNK-lite cells, i.e., CD16 downregulation was three times lower than in donor NK cells.
[0141] Example 5. Evaluation of CD16 expression on IL2-dependent cells after incubation with target cells
[0142] Donor NK cells from peripheral blood were obtained from Research Blood Components LLC (Boston, MA). MS columns (catalog number 130-042-201) and CD56 microbeads (catalog number 130-050-401) were obtained from Miltenyi Biotec (San Diego, CA). haNK003 cells and IL2-dependent cells were generated as described above. Donor NK cells, haNK003 cells, and IL2-dependent cells were co-cultured with K562 cells (American Type Culture Collection (“ATCC”), Manassas, VA) for 4 hours under normal co-culture conditions (i.e., X-VIVO 10 medium supplemented with 5% human AB serum, 37°C in a 5% CO2 incubator for 4 hours, effector-target ratio 1:1) to allow for complete cytotoxic killing of target cells. CD16 expression was first analyzed at the end of the 4-hour incubation and then again after allowing the cells to recover for another 20 hours, i.e., at the end of the 24-hour incubation. The results are summarized in Table 5, and representative figures are shown in Figure 2.
[0143] Table 5. CD16 expression after activation by contact with K562 cells
[0144]
[0145] The results showed that after co-culturing with K562 for 4 hours, CD16 expression in donor NK cells decreased by 61% ± 0.09.Cell count decreased by 4.9% ± 2.57. After overnight recovery (24 hours co-culture), CD16 in donor NK cells was downregulated to approximately 57%, while CD16 in IL2-dependent cells was downregulated to only approximately 1%, close to the original CD16 level (Figure 2). This result indicates that CD16 expression in IL2-dependent cells is stable after co-culture with K562 cells.
[0146] Example 6. Evaluation of CD16 expression on IL2-dependent cells after antibody-dependent cell-mediated cytotoxicity (ADCC)
[0147] CD16 expression levels in haNK003 and IL2-dependent cells were examined after antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC was performed by incubating cells with DOHH-2 (a CD20+ human lymphoma B cell line from ATCC) for 4 hours in the presence of 1 μg / ml rituximab (a CD20-guided cell-lysing monoclonal antibody obtained from Biogen Idec and Genentech) at an effector-target ratio of 1:0 (effector cells only) or 1:4. CD16 expression was then measured by flow cytometry, first at the end of the 4-hour incubation and then at the end of a subsequent 20-hour incubation. Results showed that CD16 expression in cells was downregulated by less than 10% after ADCC (at the end of the 4-hour co-culture). See Figure 3A for a comparison of the percentage of CD16+ cells with the percentage of CD16+ cells in the group without target cells (i.e., E:T = 1:0). Figure 3B shows the mean fluorescence intensity (MFI) of CD16 on aNKTM, haNK003, and IL2-dependent cells after the 4-hour co-culture period and after a 20-hour recovery period following ADCC (24-hour co-culture period). The results showed that CD16 remained abundant in IL2-dependent cells even after ADCC, indicating that CD16 expression in cells is highly stable in IL2-dependent cells.
[0148] Example 7. Phenotyping
[0149] Flow cytometry analysis was performed to measure the surface expression of various NK cell-specific markers, including CD3, CD56, CD16, CD337, CD54, and NKG2D of IL2-dependent clones. The results are shown in Table 6.
[0150] Table 6. Surface Expression Specification of NK Cell Specific Markers 24 / 34 Pages 27 CN 121518401 A
[0151] CD3 CD56 CD16 CD337 CD54 NKG2D aNK -0.18% 97.5% 0.36% 62.7% 96.9% 93.5% haNK-003 -0.01% 96.8% 96.8% 70.9% 95.0% 88.4% Clonal H2 -0.13% 98.3% 89.1% 21.9% 98.4%83.4% Cloned H7 -0.34% 96.9% 86.8% 58.9% 96.2% 96.2% Cloned H20 -0.51% 95.5% 91.7% 84.5% 98.3% 97.0% Cloned P74 0.19% 90.2% 73.6% 70.6% 92.2% 87.4% Cloned P82 0.27% 91.8% 83.9% 79.3% 95.3% 95.6% Cloned P110 2.20% 90.0% 74.3% 81.4% 84.8% 85.6%
[0152] The results showed that, similar to haNK-003 cells, the IL2-dependent clones exhibited positive expression of CD56, CD54, and NKG2D, which was essentially similar to the expression in aNKTM cells. All IL2-dependent clones expressed significant levels of CD16. Except for clone H2, all clones showed significant levels of CD337 expression.
[0153] Example 8. Growth Characteristics
[0154] P and H clones of aNKTM cells, haNK003 cells, and IL2-dependent cells were grown in X-VIVO 10 medium supplemented with 5% heat-inactivated human AB serum and 500 IU / mL IL-2. Cells were seeded at 10e5 cells / ml and cell numbers were measured by trypan blue exclusion on days 3, 5, and 7. Doubling time was determined based on the average of four experiments for each group, and the results are shown in Table 7 below.
[0155] Table 7. Growth characteristics
[0156] Doubling time (hours) aNK 34.8±3.9 haNK003 37.5±4.6 clone H2 34.4±3.9 clone H7 29.2±0.6 clone H20 35.8±1.4 clone P74 33.4±4.6 clone P82 36.5±3.5 clone P110 37.6±5.2
[0157] The results showed that the IL2-dependent clones had essentially similar growth rates (e.g., clones H2, H20, P74, P82, and P110) or faster growth rates (e.g., clone H7) compared to haNK-003 cells or aNKTM cells.
[0158] Example 9. Direct Cytotoxicity
[0159] K562 cells were grown in RPMI-1640 medium (Gibco / Thermofisher) supplemented with 10% heat-inactivated FBS (Gibco / Thermofisher). K562 cells and effector cells, haNK-003 cells or haNK lite cells were briefly centrifuged in 96-well plates (Falcon BD, Franklin Lakes, NJ) with different effector-target ratios and in X-VIVO supplemented with 5% human AB serum.Cells were incubated in 10 medium at 37°C in a 5% CO2 incubator for 4 hours. After incubation, cells were stained with propidium iodide (PI, Sigma-Aldrich) at 5 g / ml in 1% BSA / PBS buffer and analyzed immediately by flow cytometry. Samples were processed on a 10 flow cytometer (Miltenyi Biotec) and data were analyzed using FlowJo software.
[0160] Dead target cells, namely K562 cells, were identified as double positive for PKH67-GL and PI. Target cells and effector cells were also stained with PI to assess spontaneous cell lysis. The percentage of dead cells was determined by the percentage of PI+ in the PKH67+ target cell population. % kill was calculated as follows: [% dead target cells in sample - % spontaneously dead target cells] / [100 - % spontaneously dead target cells].
[0161] Figures 5A (P clone) and 5B (H clone) show the percentage of K562 cells lysed by the IL2-dependent clone. The results indicate that when IL2-dependent cells are co-incubated with target cells at the same effector-target ratio, they exhibit cytotoxicity that is substantially similar to or higher than that of aNK™ cells. In some cases, these IL2-dependent clones exhibit higher cytotoxicity than IL2-dependent cells.
[0162] Example 10. ADCC
[0163] Antibody-dependent cell-mediated cytotoxicity (ADCC) of IL2-dependent cells against SKBR-3 cells (ATCC, Manassas, VA) was analyzed according to the method described in Example 9, except for the additional step of pre-incubating the stained target cells with different concentrations (0.001–1 μg / mL) of monoclonal antibody, Herceptin, or allotype control antibody (“IgG”) before co-incubation with effector cells. ADCC is calculated as follows: [% kill in E+T reaction in mAb presence - % kill in E+T reaction in mAb absence] / [100 - % kill in E+T reaction in mAb absence], (E = effector cells, T = target cells). SKBR-3 cells were grown in RPMI-1640 medium (Gibco / Thermonsher) supplemented with 10% heat-inactivated FBS (Gibco / Thermofisher) before being mixed with effector cells.
[0164] As shown in Figures 6A and 6B, the IL2-dependent clone exhibited high ADCC activity, and in some cases higher than haNK-003 cells. For example, when Herceptin was present at 100 ng / ml, the ADCC activity of the H7 clone was 40% higher than that of haNK-003 cells.
[0165] Illustrative sequence
[0166] SEQ ID NO: 1 High affinity variant immunoglobulin GammaFc receptor III-A amino acid sequence (full-length form). Val at position 176 is underlined. The underlined portion at the beginning of the sequence represents the signal peptide.
[0167]
[0168] SEQ ID NO: 2 high-affinity variant immunoglobulin Gamma Fc receptor III-A nucleic acid sequence (full-length form). Instruction manual, pages 26 / 34, 29, CN 121518401 A
[0169]
[0170] SEQ ID NO: 3ER IL-2 (ER retained signal with underline) amino acid sequence
[0171]
[0172] SEQ ID NO: 4ER IL-2 nucleic acid sequence
[0173]
[0174] SEQ ID NO: 5pNEUKv1_FcRIL2 plasmid Instruction manual, pages 27 / 34, 30, CN 121518401 A
[0175] Instruction manual, pages 28 / 34, 31, CN 121518401 A
[0176]
[0177] SEQ ID NO: 6pCL20c-Mp-CD19CAR-IRES-GFP plasmid
[0178] Instruction manual, pages 29 / 34, 32, CN 121518401 A
[0179] Instruction manual, pages 30 / 34, 33, CN 121518401 A
[0180]
[0181] SEQ ID NO: 7 is the top chain of an oligonucleotide used to add additional EcoRI, SphI, and NotI restriction sites to the pCL20 MCS backbone.
[0182]
[0183] SEQ ID NO: 8 is the bottom chain of an oligonucleotide used to add additional EcoRI, SphI, and NotI restriction sites to the pCL20 MCS backbone.
[0184] SEQ ID NO: 9 Forward primer for cloning CD16
[0185]
[0186] SEQ ID NO: 10 Reverse primer for cloning CD16
[0187]
[0188] SEQ ID NO: 11 Nucleotide sequence of pCL20c-V176-CD16 plasmid Specification page 31 / 34 34 CN 121518401 A
[0189] Specification page 32 / 34 35 CN 121518401 A
[0190] Specification page 33 / 34 36 CN 121518401 A
[0191] Specification page 34 / 34 37 CN 121518401 A Specification Figure 1 / 8 page 38 CN 121518401 A Specification Figure 2 / 8 page 39 CN 121518401 A Figure 3A Specification Figure 3 / 8 Page 40 CN121518401 A Figure 3B Appendix 4 / 8 Page 41 CN 121518401 A Figure 4 Appendix 5 / 8 Page 42 CN 121518401 A Figure 5A Figure 5B Appendix 6 / 8 Page 43 CN 121518401 A Figure 6A Appendix 7 / 8 Page 44 CN 121518401 A Figure 6B Appendix 8 / 8 Page 45 CN 121518401 A Abstract The present document provides populations of IL2 Dependent haNK® cells, which express a high affinity CD16 but do not express IL-2. These cells maintain stable expression of the Fc receptor CD16 while retaining cytotoxicity. In some embodiments, the expression level of CD16 decreases no more than 20% when the cells are activated as compared to the expression level of CD16 on the cells before activation. Compositions and kits comprising the cells, and methods of making and using the IL2 Dependent haNK® cells are also provided.
Claims
1. The modified according to claim 32 Cell population, wherein the Fc receptor is CD16 (SEQ ID NO: 1), wherein the modified The cells do not express IL-2, and said population contains one or more of the modified cells. cell.
2. The modified according to claim 1 Cell population, wherein the modified The cell contains the nucleic acid CD16 (SEQ ID NO: 2).
3. The modified according to claim 1 Cell population, wherein the modified The cells exhibit antibody-dependent cell-mediated cytotoxicity (ADCC).
4. The modified according to claim 1 The cell population, when activated, showed a reduction in CD16 expression levels of no more than 20% compared to the pre-activation CD16 expression levels.
5. The modified according to claim 4 Cell population, wherein The cell population did not show a decrease in CD16 expression after activation, or the decrease in CD16 expression did not exceed 20%, and the modified... Cells maintain cytotoxic homeostasis for at least 5 hours after activation begins.
6. The modification according to any one of claims 1-4 A cell population in which the cells express higher levels of CD16 than NK cells from a donor.
7. The modified A cell population in which the percentage of CD16-positive cells decreases by no more than 20% after activation, compared to the cells before activation.
8. The modified according to claim 4 Cell populations, wherein CD16 expression was measured by flow cytometry.
9. The population according to claim 4, wherein the activation is PHA stimulation, activation via an innate pathway through co-incubation with K562 cells, or ADCC activation through co-incubation with rituximab and DOHH.
10. The population according to claim 4, wherein the cells are activated by one or more compounds selected from PMA, ionomycin, and LPS.
11. The modified according to claim 4 A cell population, wherein the cells are activated by contact with target tumor cells.
12. The modified according to claim 11 Cell population, wherein the target tumor cells are selected from K562 cells and SKBR-3 cells.
13. The modification according to claim 11 Cell population, wherein the modified cells are as described before activation Compared to other cells, CD16 expression was reduced by no more than 10%, or in some cases.
14. The modification according to claim 11 Cell population, wherein the modified cells are as described before activation Compared to other cells, CD16 expression was reduced by no more than 5%.
15. The modified according to claim 11 A cell population in which the percentage of CD16-positive cells decreases by no more than 10% after contact with the target cells, compared to the cells before contact with the target cells.
16. The modified according to claim 4 Cell population, wherein Cells are activated by contact with antibodies and target cells, wherein the incubation leads to ADCC.
17. The modified according to claim 16 The cell population, wherein the antibody is an anti-CD20 antibody and the target cells are DOHH-2 cells.
18. The modified according to claim 16 The cell population, wherein the antibody is an anti-HER2 antibody and the target cells are SKBR3 cells.
19. The modified according to claim 16 Cell population, wherein the effector-target ratio is 1:1 to 1:
10.
20. The modified according to claim 1 Cell population, wherein the modified The cells also express chimeric antigen receptors.
21. The modification according to any one of claims 1-20 Cell population, wherein the modified [cell] is present when the effector-target ratio is 5:
1. The cells exhibit at least 60% direct cytotoxicity.
22. The modification according to any one of claims 1-20 Cell population, wherein the modified The cells have at least 40% ADCC activity.
23. A method for generating modified CD16 expression that can be maintained during activation. A cell population approach, wherein the method includes introducing CD16 (SEQ ID NO: 2) instead of IL-2. In cells, where the activated modification CD16 expression on cells is not lower than that modified before activation. 50% of CD16 is expressed on the cells.
24. The method of claim 23, wherein the introduction of CD16 is achieved through lentiviral infection.
25. A kit comprising a cell population according to any one of claims 1-22.
26. The kit of claim 25, wherein the kit further comprises an antibody.
27. A pharmaceutical composition comprising a cell population of any one of claims 1-22 and a pharmaceutically acceptable excipient.
28. A method of treating a subject, comprising administering the pharmaceutical composition of claim 27 to the subject.
29. The modified according to claim 1 Cell population, wherein the modified The cells further express suicide genes.
30. The modified according to claim 29 Cell population, wherein the suicide gene is selected from thymidine kinase (TK) gene, cytosine deaminase, cytochrome P450 and iCas9.
31. A modified Fc receptor expressing Cell population, wherein the Fc receptor comprises at least 80% of the same amino acid sequence as SEQ ID NO: 1, wherein the modified The cells do not express IL-2, and the population contains one or more of the modified cells. cell.
32. The modified A cell population wherein the Fc receptor comprises at least 90% of the same amino acid sequence as SEQ ID NO: 1.
